Background: Tigecycline (TIG) is a novel glycylcycline that was approved in 2005 in the US for treatment of complicated skin and skin structure infections and complicated intra-abdominal infections. S. aureus (SA), including methicillin-resistant S. aureus (MRSA), is a leading cause of skin and skin structure infections. This study examines the in vitro activity of TIG against SA, including MRSA, over the last five years. Additionally, data were stratified according to patient location (PL) and specimen source (SS) to determine if any variation in TIG activity against SA was apparent among these subpopulations.
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Methods: SA isolates were collected from multiple locations across all nine US Bureau of Census regions during '03-'04 (N = 1,796), '05 (N = 1,802), and '06-'07 (N = 1,800) and centrally tested using broth microdilution according to current CLSI standards. TIG activity was analyzed by patient locations (PL; outpatient [OP] , intensive-care unit [ICU] , and inpatient non-ICU [IP] ) and by specimen source (SS; blood [BL] , respiratory [RP] , and skin and skin structure [SST] ). FDA breakpoints were used to interpret all TIG MIC results.
Results: Against SA overall, TIG had an MIC50/90 of 0.12/0.12 mg/L in '03-'04 and an MIC50/90 of 0.12/0.25 mg/L in both '05 and '06-'07. Throughout the study periods, percent susceptibility (%S) of TIG remained ≥99.5%. TIG activity by MIC90 was largely unaffected by methicillin susceptibility status of the isolate (MIC90: 0.12 mg/L for MSSA and 0.25 mg/L for MRSA in '03-'04, 0.25 mg/L for MSSA and MRSA in '05, [6] [7] . In each study period, the activity of TIG by MIC90 was identical among all PL (OP, ICU, and IP) and SS (BL, RP, SST) evaluated relative to TIG activity against SA overall. In the most recent study period ('06-'07), SA isolates were ≥99% S to TIG regardless of PL or SS.
Conclusion: By MIC90, TIG in vitro activity was stable against SA over the past five years spanning both its development and introduction to use and the %S of SA isolates to TIG remained unaltered and high (>99.5%). TIG activity by MIC90 was not notably affected by the methicillin susceptibility status of the isolate and was consistent across all PL and SS evaluated. Background: ␤-haemolytic streptococci (BHS), viridans group streptococci (VGS) and Streptococcus pneumoniae (SPN) are commonly occurring Gram-positive pathogens responsible for a variety of local and systemic infections. We evaluated potency of telavancin and comparators against isolates belonging to these species/groups as part of a global surveillance protocol for 2007. Telavancin is an investigational, intravenous, semi-synthetic, rapidly bactericidal lipoglycopeptide broadly active against both aerobic and anaerobic Gram-positive bacteria and has been evaluated in two Phase 3 complicated skin and skin structure infection trials.
Methods: Non-duplicate clinical isolates (1087 total) of BHS (339), VGS (100) and SPN (648) were submitted from medical centres in Europe (23), Turkey (2) and Israel (1) participating in surveillance for 2007. Identifications were confirmed by the central monitor and isolates were tested using CLSI broth microdilution.
Results: Against BHS, SPN and VGS, telavancin potency was most similar to penicillin (MIC 50 values, 0.03 vs ≤0.015-0.06 mg/L, respectively) and superior to other comparators; all tested isolates were inhibited by ≤0.25 mg/L of telavancin. Telavancin inhibited all VGS and SPN at ≤0.12 mg/L, including penicillin-non-susceptible strains (27.0% and 30.2%, respectively), and BHS at ≤0.25 mg/L. Telavancin was most active against Group A BHS (MIC 90 , 0.03 mg/L) compared with Groups B and G (0.06 and 0.12 mg/L, respectively). All streptococci were susceptible to vancomycin and linezolid, and BHS and VGS were susceptible to daptomycin. While most strains were susceptible to levofloxacin (95.0-99.4%), resistance to erythromycin/penicillin were variable (41.0/4.0%, 13.6/0.0% and 33.6/19.3% for VGS, BHS and SPN, respectively).
Conclusions cal laboratories to differentiate Streptococcus pneumoniae (Pneumococci) from other ␣-heamolytic streptococci. However, presence of optochin resistant pneumococci may lead to misidentification that will cause a compromise with treatment and prevention of pneumococcal diseases. The typical optochin susceptibility of Pneumococci resides in the Fo complex of its FoF1 H+-ATPase, an ion transport enzyme that is essential for the viability of this organism. Mechanism of optochin resistance has been attributed to a single point mutation in amino acid residues of the H+-ATPase c-subunit (atpC).
Objective: To validate the preserved isolates and identify optochin-resistant pneumococci by bile solubility test and PCR for lytA gene and to determine the mechanism of optochin resistance.
Methodology: Alpha hemolytic streptococci isolated from 4,730 nasopharyngeal swabs of children <5 years old. The isolates were validated by colony morphology, optochin susceptibility, bile solubility, PCR for lyt A (autolysin) and ATPase c-subunit genes and sequencing to detect any AA mutations.
Results: In total, 1618 ␣-haemolytic isolates were validated; 111(6.86%) were Optr ␣-heamolytic strains and only 37 (0.8%) were pneumococcus that were bile soluble and possessed lytA gene. The PCR of atpC from all 37 strains showed the presence of F0 complex in F0F1 H+-ATPase. Sequencing of atpC gene of three strains when compared with reference strain (opts strain R6) revealed the presence of nucleotide change that produces AA substitution in ATPase c-subunit protein.
Conclusion: Optochin resistant Streptococcus pneumoniae was first observed in Bangladesh. A single point mutation in H+-ATPase c-subunit gene that contributed for Optr phenotype. Reporting of Opt pneumococci as viridans streptococcus might have significant implications for the treatment and outcome of patients. Therefore, validation of ␣-haemolytic streptococci as pneumococci by bile solubility test and/or PCR should be made. 
